SynthesisBreast cancer research and treatment2013
Multigene assays and molecular markers in breast cancer: systematic review of health economic analyses.
Synthesis in Breast cancer research and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The impact of age on health utility values for older women with early-stage breast cancer: a systematic review and meta-regression.Health and quality of life outcomes · 2022Pooled it
- Cost-Effectiveness Analyses of the 21-Gene Assay in Breast Cancer: Systematic Review and Critical Appraisal.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Pooled it
- Recommendations from the EGAPP Working Group: does the use of Oncotype DX tumor gene expression profiling to guide treatment decisions improve outcomes in patients with breast cancer?Genetics in medicine : official journal of the American College of Medical Genetics · 2016Guideline
- Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling.Medical decision making : an international journal of the Society for Medical Decision Making · 2021Trial
- Cost-Utility Analysis of Multigene Assays to Guide Treatment Decisions for Node-Negative Early Breast Cancer.Oncology and therapy · 2025Article
- Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA).Breast cancer research and treatment · 2024Review
- Article
- Young Women with Breast Cancer: The Current Role of Precision Oncology.Journal of personalized medicine · 2023Review
- Cost-utility analysis of genomic profiling in early breast cancer in Colombia.Cost effectiveness and resource allocation : C/E · 2023Article
- Article
- Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.Journal of the National Cancer Institute. Monographs · 2022Review
- Nuances in the Surgical Management of Thyroid Cancer.Indian journal of surgical oncology · 2022Review
- Cost-Effectiveness Analysis from a Societal Perspective of Recurrence Index for Distant Recurrence (RecurIndex) in Women with Hormone Receptor-Positive and HER2-Negative Early-Stage Breast Cancer.Cancer management and research · 2022Article
- Hospital Rurality and Gene Expression Profiling for Early-Stage Breast Cancer among Iowa Residents (2010-2018).The breast journal · 2022Article
- Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study.Therapeutic advances in medical oncology · 2022Article
- A Novel Prognostic Four-Gene Signature of Breast Cancer Identified by Integrated Bioinformatics Analysis.Disease markers · 2022Article
- Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives.Cancers · 2021Review
- Uncovering the roles of microRNAs/lncRNAs in characterising breast cancer subtypes and prognosis.BMC bioinformatics · 2021Article
- Identification of novel cell glycolysis related gene signature predicting survival in patients with breast cancer.Scientific reports · 2021Article
- Oncotype DX Breast Recurrence ScoreMolecular diagnosis & therapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is the most common female cancer and is associated with a significant clinical and economic burden. Multigene assays and molecular markers represent an opportunity to direct chemotherapy only to patients likely to have significant benefit. This systematic review examines published health economic analyses to assess the support for adjuvant therapy decision making. Literature searches of PubMed, the Cochrane Library, and congress databases were carried out to identify economic evaluations of multigene assays and molecular markers published between 2002 and 2012. After screening and data extraction, study quality was assessed using the Quality of Health Economic Studies instrument. The review identified 29 publications that reported evaluations of two assays: Oncotype DX(®) and MammaPrint. Studies of both tests provided evidence that their routine use was cost saving or cost-effective versus conventional approaches. Benefits were driven by optimal allocation of adjuvant chemotherapy and reduction in chemotherapy utilization. Findings were sensitive to variation in the frequency of chemotherapy prescription, chemotherapy costs, and patients' risk profiles. Evidence suggests that multigene assays are likely cost saving or cost-effective relative to current approaches to adjuvant therapy. They should benefit decision making in early-stage breast cancer in a variety of settings worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.